Neuroaxonal dystrophy / NAD (RNF170-related) - Miniature American/Australian Shepherd

What does this test analyse?

This genetic test analyses the RNF170 c.367delG variant for neuroaxonal dystrophy, also known as NAD / RNF170-related NAD, in Miniature American Shepherd, Miniature Australian Shepherd and Toy Australian Shepherd.

Neuroaxonal dystrophy is an inherited neurological disorder in which nerve pathways in the brain, spinal cord or peripheral nervous system become damaged. As a result, communication between nerve cells and muscles becomes progressively disrupted.

What does this condition mean?

In this form, affected dogs can develop progressive neurological problems as young adults, with hind limb weakness, ataxia, nail or toe dragging, kyphosis and an abnormal gait.

Typical signs can include loss of coordination, ataxia, tremor, weakness, abnormal posture, toe dragging, behavioural changes, vision problems or a rapidly progressive neurological presentation. Some NAD forms start in very young puppies; other variants become visible later in life.

Inheritance and result

The trait is inherited as an autosomal recessive condition. Clear dogs have two normal copies. Carriers have one copy of the tested variant and can pass it on. Dogs with two copies have the genotype that causes this form of NAD.

Practical value of this test

• The test helps breeders identify carriers before two carriers are combined.
• The result enables targeted breeding plans without automatically losing healthy carriers from valuable lines.
• For owners, the test gives clarity about genetic risk in a breed or line where NAD occurs.
• In young dogs with neurological signs, the result can support genetic interpretation.
• Variant status can be documented reliably in pedigrees, breeding advice and long-term selection.
• For severe or early-onset NAD forms, testing helps avoid unexpected affected puppies in future combinations.

Because this NAD form can become visible later, testing before breeding use is especially valuable.